Barrington analyst Michael Petusky raised the firm’s price target on Anika Therapeutics (ANIK) to $16 from $15 and keeps an Outperform rating on the shares. The firm, which continues to think shares are “meaningfully undervalued,” says “it appears that the company agrees” based on its recent decision to commence a $15M 10b5-1 share repurchase that it expects to complete by this June.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIK: